Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
4 "Nobutaka Hattori"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Review Article
Nine Hereditary Movement Disorders First Described in Asia: Their History and Evolution
Priya Jagota, Yoshikazu Ugawa, Zakiyah Aldaajani, Norlinah Mohamed Ibrahim, Hiroyuki Ishiura, Yoshiko Nomura, Shoji Tsuji, Cid Diesta, Nobutaka Hattori, Osamu Onodera, Saeed Bohlega, Amir Al-Din, Shen-Yang Lim, Jee-Young Lee, Beomseok Jeon, Pramod Kumar Pal, Huifang Shang, Shinsuke Fujioka, Prashanth Lingappa Kukkle, Onanong Phokaewvarangkul, Chin-Hsien Lin, Cholpon Shambetova, Roongroj Bhidayasiri
J Mov Disord. 2023;16(3):231-247.   Published online June 13, 2023
DOI: https://doi.org/10.14802/jmd.23065
  • 2,303 View
  • 214 Download
AbstractAbstract PDFSupplementary Material
Clinical case studies and reporting are important to the discovery of new disorders and the advancement of medical sciences. Both clinicians and basic scientists play equally important roles leading to treatment discoveries for both cures and symptoms. In the field of movement disorders, exceptional observation of patients from clinicians is imperative, not just for phenomenology but also for the variable occurrences of these disorders, along with other signs and symptoms, throughout the day and the disease course. The Movement Disorders in Asia Task Force (TF) was formed to help enhance and promote collaboration and research on movement disorders within the region. As a start, the TF has reviewed the original studies of the movement disorders that were preliminarily described in the region. These include nine disorders that were first described in Asia: Segawa disease, PARK-Parkin, X-linked dystonia-parkinsonism, dentatorubral-pallidoluysian atrophy, Woodhouse-Sakati syndrome, benign adult familial myoclonic epilepsy, Kufor-Rakeb disease, tremulous dystonia associated with mutation of the calmodulin-binding transcription activator 2 gene, and paroxysmal kinesigenic dyskinesia. We hope that the information provided will honor the original researchers and help us learn and understand how earlier neurologists and basic scientists together discovered new disorders and made advances in the field, which impact us all to this day.
Letter to the editor
Continuous 24-h Levodopa-Carbidopa Intestinal Gel Infusion After a Levodopa Holiday Suppressed Refractory Dyskinesia Despite Increasing Levodopa Dose
Noriko Nishikawa, Taku Hatano, Daiki Kamiyama, Haruna Haginiwa-Hasegawa, Genko Oyama, Nobutaka Hattori
J Mov Disord. 2022;15(3):290-292.   Published online July 26, 2022
DOI: https://doi.org/10.14802/jmd.22021
  • 1,294 View
  • 123 Download
PDFSupplementary Material
Brief communications
Current Status of Telemedicine for Parkinson’s Disease in Japan: A Single-Center Cross-Sectional Questionnaire Survey
Mayuko Ogawa, Genko Oyama, Satoko Sekimoto, Taku Hatano, Nobutaka Hattori
J Mov Disord. 2022;15(1):58-61.   Published online December 24, 2021
DOI: https://doi.org/10.14802/jmd.21096
  • 4,376 View
  • 231 Download
  • 6 Web of Science
  • 7 Crossref
AbstractAbstract PDFSupplementary Material
Objective
Using telemedicine is a way to improve the accessibility of specialists for patients with Parkinson’s disease (PD); however, it is not widely used in Japan. We investigated the efficacy of telemedicine in PD by using a single-center cross-sectional questionnaire survey.
Methods
We sent a questionnaire to patients who agreed to participate from among 52 patients with PD who had used telemedicine services at Juntendo University Hospital from October 2017 to November 2018. Caregivers were asked to respond to one question separately.
Results
A total of 38 patients responded to the questionnaire. Most patients were satisfied with the telemedicine consultation (7.8 ± 1.9), reporting that it was effective in reducing their travel burden. Twenty-one patients attended a telemedicine consultation with their caregivers, and their satisfaction was high (8.4 ± 1.8).
Conclusion
In a specific cohort in Japan, patients with PD and their caregivers were mostly satisfied with the telemedicine service.

Citations

Citations to this article as recorded by  
  • Effects of LSVT-BIG via telerehabilitation on non-motor and motor symptoms and quality of life in Parkinson’s disease
    Yasemin Ekmekyapar Fırat, Türkan Turgay, Selver Seval Soğan, Pınar Günel Karadeniz
    Acta Neurologica Belgica.2023; 123(1): 207.     CrossRef
  • A Narrative Review of Current Status and Future Perspective of Telemedicine for Parkinson's Disease, Dementia, and Intractable Neurological Diseases in Japan
    GENKO OYAMA, MAYUKO OGAWA, SATOKO SEKIMOTO, TAKU HATANO, NOBUTAKA HATTORI
    Juntendo Medical Journal.2023; 69(1): 14.     CrossRef
  • A multicenter, prospective, observational study to assess the satisfaction of an integrated digital platform of online medical care and remote patient monitoring in Parkinson's disease
    Makoto Shiraishi, Tsutomu Kamo, Ryuya Kumazawa, Naoshi Sasaki, Kenji Isahaya, Hisanao Akiyama, Yoshihiko Furusawa, Reiko Onodera, Jovelle Fernandez, Masaru Otsuka, Yoshihisa Yamano
    Neurology and Clinical Neuroscience.2023; 11(3): 152.     CrossRef
  • New era of artificial intelligence and machine learning-based detection, diagnosis, and therapeutics in Parkinson’s disease
    Rohan Gupta, Smita Kumari, Anusha Senapati, Rashmi K. Ambasta, Pravir Kumar
    Ageing Research Reviews.2023; 90: 102013.     CrossRef
  • Feasibility study of Internet video-based speech-language activity for outpatients with primary progressive aphasia
    Shinji Higashi, Yuko Koshibe, Takehiro Miyazaki, Ryohei Watanabe, Hanako Nakanome, Takeshi Inoue, Takashi Asada, Tetsuaki Arai, Kenjiro Ono
    PLOS ONE.2023; 18(7): e0288468.     CrossRef
  • Feasibility and efficacy of video-call speech therapy in patients with Parkinson's disease: A preliminary study
    Hee Jin Chang, Jiae Kim, Jae Young Joo, Han-Joon Kim
    Parkinsonism & Related Disorders.2023; 114: 105772.     CrossRef
  • Perspectives on Telemedicine
    彦光 大山, 信孝 服部
    Iryou kikigaku (The Japanese journal of medical instrumentation).2022; 92(3): 331.     CrossRef
Rescue Levodopa/Carbidopa Intestinal Gel for Secondary Deep Brain Stimulation Failure
Juan Miguel Pilar Bautista, Genko Oyama, Maierdanjiang Nuermaimaiti, Satoko Sekimoto, Fuyuko Sasaki, Taku Hatano, Kenya Nishioka, Masanobu Ito, Atsushi Umemura, Yuji Ishibashi, Yasushi Shimo, Nobutaka Hattori
J Mov Disord. 2020;13(1):57-61.   Published online January 31, 2020
DOI: https://doi.org/10.14802/jmd.19051
  • 5,692 View
  • 152 Download
  • 6 Web of Science
  • 6 Crossref
AbstractAbstract PDF
Objective
The long-term efficacy of deep brain stimulation (DBS) for motor fluctuations in advanced Parkinson’s disease (PD) has been well established; however, motor fluctuations may recur over time despite multiple adjustments of DBS settings and medications.
Methods
We conducted a retrospective chart review of three patients for whom levodopa-carbidopa intestinal gel (LCIG) was additionally administered as a rescue therapy for secondary DBS failure due to the recurrence of motor fluctuations.
Results
The three patients had advanced PD with a disease duration of 14–19 years, and had undergone DBS for motor fluctuations refractory to standard medical management. LCIG was administered to the patients because of symptom recurrence years after DBS and provided complementary effects in all patients.
Conclusion
The cases presented here show that rescue LCIG therapy may be a complementary treatment option for patients with post-DBS advanced PD who have a recurrence of troublesome motor complications.

Citations

Citations to this article as recorded by  
  • Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease
    Dominik Pürner, Mohammad Hormozi, Daniel Weiß, Michael T. Barbe, Hannah Jergas, Tino Prell, Eileen Gülke, Monika Pötter-Nerger, Björn Falkenburger, Lisa Klingelhöfer, Pia K. Gutsmiedl, Bernhard Haslinger, Angela M. Jochim, Andreas Wolff, Nils Schröter, Mi
    Neurology.2023;[Epub]     CrossRef
  • Combining Device‐Aided Therapies in Parkinson's Disease: A Case Series and a Literature Review
    Iro Boura, Nikolaos Haliasos, Ιrene‐Areti Giannopoulou, Dimitrios Karabetsos, Cleanthe Spanaki
    Movement Disorders Clinical Practice.2021; 8(5): 750.     CrossRef
  • Combined and Sequential Treatment with Deep Brain Stimulation and Continuous Intrajejunal Levodopa Infusion for Parkinson’s Disease
    Daniël van Poppelen, Annelie N.M. Tromp, Rob M.A. de Bie, Joke M. Dijk
    Journal of Personalized Medicine.2021; 11(6): 547.     CrossRef
  • Personalised Advanced Therapies in Parkinson’s Disease: The Role of Non-Motor Symptoms Profile
    Valentina Leta, Haidar S. Dafsari, Anna Sauerbier, Vinod Metta, Nataliya Titova, Lars Timmermann, Keyoumars Ashkan, Michael Samuel, Eero Pekkonen, Per Odin, Angelo Antonini, Pablo Martinez-Martin, Miriam Parry, Daniel J. van Wamelen, K. Ray Chaudhuri
    Journal of Personalized Medicine.2021; 11(8): 773.     CrossRef
  • Parkinson’s Kinetigraph in the Selection of Levodopa-Carbidopa Intestinal Gel for Motor Fluctuations Refractory to Deep Brain Stimulation
    Yassine Noui, Monty Adam Silverdale, Julian Evans, Lucy Partington-Smith, Christopher Kobylecki
    Journal of Movement Disorders.2021; 14(3): 239.     CrossRef
  • The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When?
    Joke M. Dijk, Alberto J. Espay, Regina Katzenschlager, Rob M.A. de Bie, Bastiaan R. Bloem, Patrik Brundin
    Journal of Parkinson's Disease.2020; 10(s1): S65.     CrossRef

JMD : Journal of Movement Disorders